Blog
RSS FeedPosted by Michael Wonder on 29 Jun 2024
NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix
28 June 2024 - NICE has recommended CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) for immediate reimbursement by ...
Posted by Michael Wonder on 22 Jun 2024
Vertex announces extended long-term reimbursement agreement with NHS England for access to cystic fibrosis medicines Kaftrio, Symkevi and Orkambi
20 June 2024 - Agreement includes access to any future licence extensions. ...
Posted by Michael Wonder on 22 Jun 2024
NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults
21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment ...
Posted by Michael Wonder on 20 Jun 2024
Quality adjusted life years, quality adjusted life year like measures, or neither? The debate continues.
19 June 2024 - The quality-adjusted life year (QALY) is over 50 years old. Debate about the ethical basis for the ...
Posted by Michael Wonder on 19 Jun 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)
19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...
Posted by Michael Wonder on 13 Jun 2024
House dust mite allergen for the treatment of patients with allergic rhinitis and allergic asthma caused by house dust mites (review of TA834)
13 June 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 13 Jun 2024
Comparing new medicine availability across Europe
12 June 2024 - Each year, the European Pharmaceutical Industry Association (EFPIA) publishes data comparing the availability of new medicines across ...
Posted by Michael Wonder on 13 Jun 2024
Baricitinib for the treatment of patients with juvenile idiopathic arthritis
13 June 2024 - NICE is unable to make a recommendation on the use in the NHS of baricitinib (Olumiant) for ...
Posted by Michael Wonder on 12 Jun 2024
Pembrolizumab in combination with trastuzumab and chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 June 2024 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with trastuzumab and ...
Posted by Michael Wonder on 12 Jun 2024
Voxelotor for the treatment of patients with haemolytic anaemia caused by sickle cell disease
12 June 2024 - NICE has published final evidence-based recommendations on the use of voxelotor (Oxbryta) for the treatment of ...
Posted by Michael Wonder on 11 Jun 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments
6 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 08 Jun 2024
Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria
29 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Jun 2024
Ivosidenib in combination with azacitidine for the first-line treatment of patients with IDH1 R132 mutation positive acute myeloid leukaemia (final guidance)
5 June 2024 - NICE has published final evidence-based guidance on the use of ivosidenib with azacitidine in the NHS ...
Posted by Michael Wonder on 05 Jun 2024
Nivolumab for the adjuvant treatment of patients 12 years and older with completely resected melanoma at high risk of recurrence
5 June 2024 - NICE is unable to make a recommendation on the use of nivolumab (Opdivo) for the adjuvant treatment ...
Posted by Michael Wonder on 04 Jun 2024
Mounjaro is second obesity drug to be approved for use in England
4 June 2024 - Those with BMI of at least 35 kg.m2 and a co-morbidity can now be prescribed tirzepatide and ...